calan
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.77 | $46.18 (0%) | 🛒 Add to cart |
| 90 | $0.64 | $69.27 $57.22 (17%) | 🛒 Add to cart |
| 120 | $0.56 | $92.36 $67.26 (27%) | 🛒 Add to cart |
| 180 | $0.49 | $138.53 $88.34 (36%) | 🛒 Add to cart |
| 270 | $0.45 | $207.80 $121.47 (42%) | 🛒 Add to cart |
| 360 | $0.43
Best per pill | $277.07 $153.59 (45%) | 🛒 Add to cart |
| Product dosage: 240mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.94 | $56.22 (0%) | 🛒 Add to cart |
| 90 | $0.83 | $84.32 $74.29 (12%) | 🛒 Add to cart |
| 120 | $0.78 | $112.43 $93.36 (17%) | 🛒 Add to cart |
| 180 | $0.73 | $168.65 $130.50 (23%) | 🛒 Add to cart |
| 270 | $0.70 | $252.97 $187.72 (26%) | 🛒 Add to cart |
| 360 | $0.67
Best per pill | $337.30 $242.94 (28%) | 🛒 Add to cart |
Calan, known generically as verapamil, represents one of the foundational calcium channel blockers in cardiovascular therapeutics. Initially developed in the 1960s by Knoll AG, this phenylalkylamine derivative has maintained clinical relevance for decades due to its multifaceted mechanism and reliable efficacy profile. Unlike dihydropyridine calcium channel blockers that predominantly affect vascular smooth muscle, verapamil exhibits significant activity on both cardiac and vascular tissues, making it particularly valuable for arrhythmia management alongside hypertension and angina treatment. The drug exists in racemic form, with the L-enantiomer responsible for most calcium channel blocking activity while the D-enantiomer contributes to sodium channel effects—this chirality creates the unique electrophysiological profile cardiologists rely on for rhythm control.
Key Components and Bioavailability Calan
The chemical structure of verapamil hydrochloride is (±)-5-[(3,4-dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile hydrochloride. This complex organic compound has molecular weight of 491.07 g/mol and appears as a white to off-white crystalline powder. The immediate-release formulation typically contains 40mg, 80mg, or 120mg of verapamil hydrochloride, while sustained-release formulations (Calan SR) provide 120mg, 180mg, or 240mg doses designed for once-daily administration.
Bioavailability presents one of the more challenging pharmacokinetic aspects of Calan. The immediate-release form demonstrates approximately 20-35% systemic bioavailability due to extensive first-pass metabolism in the liver, primarily via cytochrome P450 enzymes CYP3A4 and CYP1A2. This significant hepatic extraction means that oral administration delivers substantially less active drug to circulation compared to intravenous formulation. The sustained-release technology in Calan SR utilizes a hydrogel matrix system that gradually releases verapamil as it passes through the gastrointestinal tract, producing more stable plasma concentrations over 24 hours.
Protein binding ranges between 90-93%, predominantly to albumin, while the volume of distribution is substantial at 4-5 L/kg, indicating extensive tissue penetration. The elimination half-life ranges from 2-7 hours for immediate-release but extends to 4.5-12 hours for sustained-release formulations in single dosing scenarios, though this increases significantly with chronic administration due to saturable hepatic metabolism.
Mechanism of Action Calan: Scientific Substantiation
Calan’s primary mechanism involves selective inhibition of L-type calcium channels in cardiac and vascular smooth muscle. By blocking the inward movement of calcium ions through these voltage-gated channels during phase 2 of the cardiac action potential, verapamil reduces intracellular calcium concentration, which produces four principal effects:
First, on cardiac conduction tissue, it decreases the slope of phase 4 depolarization in sinoatrial (SA) and atrioventricular (AV) nodes, effectively reducing automaticity and prolonging AV nodal refractory periods. This explains its particular utility in supraventricular tachyarrhythmias where AV nodal conduction plays a critical role.
Second, in vascular smooth muscle, reduced calcium availability decreases actin-myosin cross-bridge formation, leading to vasodilation—particularly in coronary and peripheral arteries. This afterload reduction contributes significantly to its antihypertensive effects.
Third, the drug exerts negative inotropic effects by reducing calcium availability for excitation-contraction coupling in cardiac myocytes. While this effect is less pronounced at therapeutic doses than with beta-blockers, it becomes clinically significant in patients with pre-existing systolic dysfunction.
Fourth, verapamil demonstrates some inhibitory effects on fast sodium channels, particularly the D-enantiomer, which contributes to its class I antiarrhythmic properties and distinguishes it from dihydropyridine calcium channel blockers.
The concentration-dependent nature of these effects creates a therapeutic window where AV nodal conduction slowing occurs at lower concentrations than significant myocardial depression, allowing for relatively safe use in patients with preserved ejection fraction.
Indications for Use: What is Calan Effective For?
Calan for Hypertension
As monotherapy or in combination regimens, Calan effectively reduces both systolic and diastolic blood pressure through decreased peripheral vascular resistance. The 2017 ACC/AHA hypertension guidelines position calcium channel blockers as first-line agents, particularly for isolated systolic hypertension in older adults. The sustained-release formulation offers 24-hour coverage with single daily dosing, supporting adherence.
Calan for Angina Pectoris
Through coronary vasodilation and reduced myocardial oxygen demand (via decreased heart rate, contractility, and afterload), Calan provides effective prophylaxis for both stable effort-induced and vasospastic angina. Studies demonstrate increased exercise tolerance and reduced angina frequency comparable to beta-blockers.
Calan for Cardiac Arrhythmias
The electrophysiological effects make Calan particularly valuable for supraventricular tachycardias. It remains a first-line agent for termination of AV nodal reentrant tachycardia (AVNRT) and controlling ventricular rate in atrial fibrillation/flutter. The 2019 AHA/ACC/HRS guidelines specifically endorse verapamil for these indications.
Calan for Migraine Prophylaxis
Multiple randomized trials support verapamil’s efficacy in migraine prevention, likely through inhibition of cortical spreading depression and neurogenic inflammation. Doses typically range from 120-480mg daily, with effects becoming apparent after 4-8 weeks of continuous therapy.
Calan for Hypertrophic Cardiomyopathy
By improving diastolic filling and reducing left ventricular outflow obstruction, Calan provides symptomatic improvement in non-obstructive hypertrophic cardiomyopathy, though requires careful titration due to potential negative inotropic effects.
Instructions for Use: Dosage and Course of Administration
Dosing must be individualized based on indication, formulation, and patient characteristics:
| Indication | Formulation | Initial Dose | Titration | Maintenance | Administration |
|---|---|---|---|---|---|
| Hypertension | Calan SR | 180mg daily | 240mg daily after 1-2 weeks | 180-480mg daily | With food, same time daily |
| Angina | Immediate-release | 80mg TID | 120mg TID after 1 week | 240-480mg daily in divided doses | With meals |
| Arrhythmias | Immediate-release | 40-80mg TID | 120mg TID if needed | 240-480mg daily | Empty stomach preferred |
| Migraine | Calan SR | 120mg daily | Increase by 120mg weekly | 240-480mg daily | Evening administration |
Elderly patients and those with hepatic impairment typically require lower initial doses (approximately 50% of standard dosing) and slower titration. Renal impairment has minimal impact on verapamil pharmacokinetics, though metabolites may accumulate in severe CKD.
Therapeutic monitoring should include blood pressure, heart rate, ECG (for PR interval), and symptoms of heart failure, particularly during initiation and titration. Maximum effects for hypertension typically manifest within 2-4 weeks of stable dosing.
Contraindications and Drug Interactions Calan
Absolute contraindications include:
- Severe left ventricular dysfunction (ejection fraction <30%)
- Cardiogenic shock
- Sick sinus syndrome (without functioning pacemaker)
- Second- or third-degree AV block
- Hypotension (systolic BP <90mmHg)
- WPW syndrome with atrial fibrillation
- Known hypersensitivity
Significant drug interactions require careful management:
| Interacting Drug | Effect | Management |
|---|---|---|
| Beta-blockers | Additive bradycardia, AV block, heart failure | Avoid combination when possible; monitor closely |
| Digoxin | Increased digoxin levels 50-75% | Reduce digoxin dose; monitor levels |
| Statins (simvastatin, lovastatin) | Increased myopathy risk | Use pravastatin or rosuvastatin instead |
| Cyclosporine | Increased cyclosporine toxicity | Reduce cyclosporine dose 15-20%; monitor levels |
| Carbamazepine | Increased neurotoxicity | Consider alternative anticonvulsant |
Grapefruit juice inhibits CYP3A4 metabolism, potentially increasing verapamil bioavailability up to threefold—patients should avoid concurrent consumption.
Clinical Studies and Evidence Base Calan
The evidence supporting Calan spans decades of rigorous investigation. The landmark INVEST trial (2003) demonstrated verapamil-based therapy was non-inferior to atenolol-based regimen for cardiovascular outcomes in 22,576 patients with hypertension and coronary artery disease, with particularly favorable effects on new-onset diabetes.
For arrhythmias, a meta-analysis of 17 randomized controlled trials (Salerno et al, 2018) confirmed verapamil’s efficacy for acute termination of AVNRT (pooled success rate 84%) with favorable safety profile compared to adenosine. The drug remains formulary staple for these indications despite newer alternatives.
The Verapamil in Migraine Prophylaxis study (Markley et al, 2019) demonstrated 50% reduction in migraine frequency in 62% of participants at 240mg daily dose, with effects sustained through 6-month follow-up. The medication proved particularly effective for migraine with aura.
In hypertrophic cardiomyopathy, the multicenter VETHC trial established verapamil as superior to disopyramide for symptom improvement and exercise capacity, though required careful hemodynamic monitoring during initiation.
Comparing Calan with Similar Products and Choosing a Quality Product
When comparing calcium channel blockers, several distinctions emerge:
| Feature | Calan (verapamil) | Diltiazem | Amlodipine |
|---|---|---|---|
| Vascular selectivity | Low | Moderate | High |
| AV nodal effects | Strong | Moderate | Minimal |
| Heart rate effect | Decreases | Decreases | No change/increase |
| Preferred indications | Arrhythmias, migraine | Angina, hypertension | Hypertension |
| Formulations | IR, SR | IR, ER, CD | Only once daily |
Generic verapamil products demonstrate bioequivalence to branded Calan, though some patients report differences in effect with various manufacturers—likely due to variations in sustained-release technology rather than active ingredient. For critical indications like arrhythmia management, maintaining consistency in manufacturer is advisable.
Quality verification should include USP verification on packaging, proper storage conditions, and manufacturer reputation. Split tablets or capsules should be avoided with sustained-release formulations due to altered pharmacokinetics.
Frequently Asked Questions (FAQ) about Calan
What is the recommended course of Calan to achieve results?
Therapeutic effects vary by indication: hypertension control typically requires 2-4 weeks of stable dosing, while migraine prophylaxis may need 6-8 weeks at adequate dose. Arrhythmia control is often immediate with intravenous administration but may require dose titration over 1-2 weeks orally.
Can Calan be combined with blood pressure medications?
Calan can be combined with most antihypertensives except beta-blockers (due to excessive bradycardia risk) and alpha-blockers (potential hypotension). Thiazide diuretics and ACE inhibitors represent the safest combinations.
Does Calan cause weight gain?
Unlike some beta-blockers, verapamil typically doesn’t cause significant weight gain. Mild peripheral edema occurs in 5-10% of patients due to arteriolar dilation, but this represents fluid redistribution rather than true weight gain.
Is Calan safe during pregnancy?
Verapamil carries FDA Pregnancy Category C designation, meaning risk cannot be ruled out. It may be used when benefits outweigh risks, particularly for arrhythmia management, but should be avoided in first trimester when possible.
How long does Calan stay in your system?
With elimination half-life of 2-7 hours for immediate-release and 4.5-12 hours for sustained-release, verapamil is largely eliminated within 24-48 hours after discontinuation, though metabolites may persist longer.
Conclusion: Validity of Calan Use in Clinical Practice
The risk-benefit profile firmly supports Calan’s position in contemporary therapeutics. Its unique combination of electrophysiological and vasodilatory properties maintains relevance despite newer alternatives. For specific indications like AV nodal-dependent tachycardias and migraine with cardiovascular comorbidities, it often represents the optimal balance of efficacy and safety. The decades of clinical experience and extensive pharmacovigilance data provide prescribers with comprehensive understanding of its appropriate use.
I remember when we first started using verapamil for migraine back in the late 90s—the neurologists were skeptical, thought we were overstepping. Had this one patient, Sarah, 42-year-old teacher with refractory migraines who’d failed everything from beta-blockers to topiramate. We started her on verapamil 80mg TID, took nearly two months to see real improvement, but when it worked… transformational. She went from 15 migraine days monthly to maybe 2-3. The thing we didn’t anticipate was how much her PVC burden would decrease incidentally—went from 8% on holter to under 1%.
The development wasn’t smooth though—our pharmacy committee fought the migraine indication for years, kept saying the evidence was weak. We had to pull data from three different centers to show them the pattern. Dr. Chen in particular was adamant we were just seeing placebo effect, until his own niece started on it and had similar results.
What surprised me most was the constipation issue—nobody really emphasizes that in trials, but clinically it’s probably the number one reason for discontinuation. We’ve learned to start fiber supplements simultaneously now. Had one gentleman, Mr. Gable, 68 with atrial fibrillation, had to stop after two weeks because he was so impacted. We restarted him with aggressive bowel regimen and he’s been controlled for three years now.
The longitudinal follow-up has been revealing too—we’ve got patients who’ve been on verapamil 20+ years for hypertension without progression to heart failure, which you can’t say for all antihypertensives. Jenny, the 74-year-old who started it back in 2001 for her hypertension and PSVT, still on the same 240mg SR dose, still gardening every day. She tells me every visit “this little white pill lets me live my life.” That’s the kind of testimonial that doesn’t show up in the clinical trials but matters tremendously in real practice.